Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate to Severe Acne Vulgaris Clear all
Completed Phase 2 Interventional Results available

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab (M1095), Adalimumab, Placebo
Drug · Other
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00612573
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years to 45 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
23
States / cities
Encino, California • Fremont, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 16 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

NCT01559922
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Normal Saline, Artefill
Drug · Device
Lead sponsor
Suneva Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Beverly Hills, California • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

NCT02421172
View directory record Official record
Conditions
Hidradenitis Suppurativa (Acne Inversa)
Interventions
CJM112, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Ormond Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 10, 2026, 1:34 PM EDT
Terminated Not applicable Interventional Results available

Laser Treatment of Moderate to Severe Acne Vulgaris

NCT04466527
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Laser Intervention
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242446
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01815450
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, BLI1100 - modified formulation, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Fremont, California • Jacksonville, Florida • Ormond Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 4 Interventional

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

NCT00437151
View directory record Official record
Conditions
Acne
Interventions
More frequent than normal office visits, Electronic reminders (voice, e-mail, text messages), Parenteral involvement / intervention reminders, No intervention or reminders
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 10, 2026, 1:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 10, 2026, 1:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
BFB759, Placebo for BFB759
Biological · Other
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Encino, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne

NCT01591304
View directory record Official record
Conditions
Facial Acne
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Woodland Hills, California • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01241331
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, Vehicle cream
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • Oceanside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 10, 2026, 1:34 PM EDT
Active, not recruiting Not applicable Interventional

Study on Using Radiofrequency to Treat Moderate to Severe Acne

NCT06315166
View directory record Official record
Conditions
Moderate to Severe Acne Vulgaris
Interventions
triLift/Legend Pro+ Fractional RF System
Device
Lead sponsor
Pollogen
Industry
Eligibility
18 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Grosse Pointe, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433
View directory record Official record
Conditions
Acne Vulgaris
Interventions
aminolevulinic acid HCL (ALA), Vehicle (VEH)
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 10, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Treatment for Moderate to Severe Acne

NCT01206348
View directory record Official record
Conditions
Acne
Interventions
Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years to 30 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Santa Monica, California • Hockessin, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 10, 2026, 1:34 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

NCT02796066
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, TSN2898
Drug
Lead sponsor
Thesan Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 10, 2026, 1:34 PM EDT